Progress in antisense therapeutics

Medicinal Research Reviews

Volumn 16, Issue 4, 1996, Pages 319-344

  Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; NUCLEIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN; RIBONUCLEASE; RNA;

BINDING AFFINITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SPECIFICITY; HUMAN; HYBRIDIZATION; MOLECULAR BIOLOGY; NONHUMAN; RECEPTOR OCCUPANCY; REVIEW; RNA SPLICING; RNA TRANSLATION;

EID: 0030056240     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-1128(199607)16:4<319::aid-med2>3.0.co;2-#     Document Type: Review

References (183)

1. S. T. Crooke, Therapeutic Applications of Oligonucleotides, R. G. Landes Co., Austin, TX, 1995.
2. D. E. Crooke and S. T. Crooke, "Combinatorial drug discovery. Which methods will produce the greatest value?" BioTechnology, 13, 351 (1995).
3. C. A. Stein and Y.-C. Cheng, "Antisense oligonucleotides as therapeutic agents - Is the bullet really magic?" Science, 261, 104 (1993).
4. R. W. Wagner, "Gene inhibition using antisense oligodeoxynucleotides." Nature, 372, 333 (1994).
5. K. J. Breslauer, R. Frank, and H. Blocker, "Predicting DNA duplex stability from base sequence," Proc. Natl. Acad. Sci. U.S.A., 83, 3746 (1986).
6. S. M. Freier, R. Kierezek, J. Jaeger, et al., "Improved free-energy parameters for predictions of RNA duplex stability." Proc. Natl. Acad. Sci. U.S.A., 83, 9373 (1986).
7. S. M. Freier, W. F. Lima, Y. S. Sanghvi, et al., "Thermodynamics of antisense oligonucleotide hybridization," in Gene Regulation by Antisense Nucleic Acids, J. Izant and R. Erickson, Eds., Raven Press, New York, 1992, p. 95.
8. S. L. Thein and R. B. Wallace, "The use of synthetic oligonucleotides as specific hybridization probes in the diagnosis of genetic disorders," In Human Genetic Diseases: A Practical Approach, K. E. Davies, ed., IRL Press, Oxford, p. 33, 1986.
9. C. Helene and J. J. Toulme, "Control of gene expression by oligonucleotides covalently linked to intercalating agents and nucleic acid-cleaving reagents," in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, J. S. Cohen, Eds., CRC Press, Boca Raton, FL, 1989, p. 137.
10. C. Helene and J. J. Toulme, "Specific regulation of gene expression by antisense, sense and antigene nucleic acids," Biochim. Biophys. Acta, 1049, 99 (1990).
11. B. P. Monia, J. F. Johnston, D. J. Ecker, et al., "Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides," J. Biol. Chem., 267, 19954 (1992).
12. M. E. McManaway, L. M. Neckers, S. L. Loke, et al., "Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide," Lancet, 335, 808 (1990).
13. M. Kulka, C. Smith, L. Aurelian, et al., "Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonates) complementary to the acceptor splice junction of herpes simplex virus type 1 immediately early mRNA," Proc. Natl Acad. Sci. U.S.A., 86, 6868 (1989).
14. P. C. Zamecnik, J. Goodchild, Y. Taguchi, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA," Proc. Natl. Acad. Sci. U.S.A., 83, 4143 (1986).
15. C. C. Smith, L. Aurelian, M. P. Reddy, et al. "Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5," Proc. Natl. Acad. Sci. U.S.A., 83, 2787 (1985).
16. Z. Dominski and R. Kole, "Restoration of correct splicing in thalassemic pre-mRNA by antisenses oligonucleotides," Proc. Natl. Acad. Sci., 90, 8673 (1993).
17. S. Agrawal, J. Goodchild, M. P. Civeira, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," Proc. Natl Acad. Sci. U.S.A., 85, 7079 (1988).
18. M. Lemaitre, B. Bayard, and B. Lebleu, "Specific antiviral activity of a poly (1-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N-protein mRNA initiation site," Proc. Natl. Acad. Sci. U.S.A., 84, 648 (1987).
19. A. Rosolen, L. Whitesell, M. Olegalo, et al., "Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line," Cancer Res., 50, 6316 (1990).
20. G. Vasanthakumar and N. K. Ahmed, "Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates," Cancer Commun., 1, 225 (1989).
21. A. R. Sburlati, R. E. Manrow, and S. L. Berger, "Prothymosin a antisense oligomers inhibit myeloma cell division," Proc. Natl. Acad. Sci. U.S.A., 88, 253 (1991).
22. H. Zheng, B. M. Sahai, P. Kilgannon, et al., "Specific inhibition of cell-surface T-cell receptor expression by antisense oligodeoxynucleotides and its effect on the production of an antigen-specific regulatory T-cell factor. Proc. Natl Acad. Sci. U.S.A., 86, 3758 (1989).
23. J. A. M. Maier, P. Voulalas, D. Roeder, et al., "Extension of the life-span of human endothelial cells by an interleukin-1α antisense oligomer," Science, 249, 1570 (1990).
24. C. K. Mirabelli, C. F. Bennett, K. Anderson, et al., "In vitro and in vivo pharmacologic activities of antisense oligonucleotides," Anti-Cancer Drug Design, 6, 647 (1991).
25. 2 mRNA of papillomavirus: Potential treatment of genital warts," Antimicrobial Agents and Chemotherapy, 37, 171 (1993).
26. T. Vickers, B. F. Baker, P. D. Cook, et al., "Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element," Nucleic Adds Res., 19, 3359 (1991).
27. D. J. Ecker, T. A. Vickers, T. W. Bruice, et al., "Pseudo-half knot formation with RNA," Science, 257, 958 (1992).
28. S. K. Saxena and E. J. Ackerman, "Microinjected oligonucleotides complementary to the α-sarcin loop of 28 S RNA abolish protein synthesis in xenopus oocytes," J. Biol. Chem., 265, 3263 (1990).
29. K. Walker, S. A. Elela, and R. N. Nazar, "Inhibition of protein synthesis by anti-5.8 S rRNA oligodeoxyribonucleotides," J. Biol. Chem., 265, 2428 (1990).
30. P. Westerman, B. Gross, and G. Hoinkis, "Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides," Biomed. Biochim. Acta, 48, 85 (1989).
31. B. Baker, "Decapitation of a 5′ capped oligoribonucleotide by ortho-Phenanthroline:Cu(II)," J. Am. Chem. Soc., 115, 3378 (1993).
32. B. F. Baker, L. Miraglia, and C. H. Hagedorn, "Modulation of eurkaryotic initiation factor-4E binding to 5′ capped oligoribonucleotides by modified antisense oligonucleotides," J. Biol. Chem., 267, 11495 (1992).
33. M. Y. Chiang, H. Chan, M. A. Zounes, et al., "Antisense oligonucleotides inhibit ICAM-1 expression by two distinct mechanisms," J. Biol. Chem., 266, 18162 (1991).
34. P. C. Zamecnik and M. L. Stephenson, "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotides," Proc. Natl. Acad. Sci. U.S.A., 75, 280 (1978).
35. A. Zerial, N. T. Thuong, and C. Helene, "Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent," Nucleic Acids Res., 15, 9909 (1987).
36. N. T. Thuong, U. Asseline, and T. Monteney-Garestier, "Oligodeoxynucleotides covalently linked to intercalating and reactive substances: Synthesis, characterization and physicochemical studies," in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Inc., 1989, p. 25.
37. R. J. Crouch and M.-L. Dirksen, "Ribonucleases H.," in Nucleases, S. M. Linn and R. J. Roberts, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY,1985, p. 211,.
38. C. Crum, J. D. Johnson, A. Nelson, et al., "Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro," Nucleic Acids. Res., 16, 4569 (1988).
39. M. T. Haeuptle, R. Frank, and B. Dobberstein, "Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length," Nucleic Acids Res., 14, 1427 (1986).
40. H. Doris-Keller, "Site specific enzymatic cleavage of RNA," Nucleic Acid Res., 7, 179 (1979).
41. A. M. Kawasaki, M. D. Casper, S. M. Freier, et al., "Uniformly modified 2′-deoxy-2′ fluoro phosphorothioate oligonucleotides as nuclease resistant antisense compounds with high affinity and specificity for RNA targets," J. Med. Chem., 36, 831 (1993).
42. B. S. Sproat, A. L. Lamond, B. Beijer, et al., "Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases," Nucleic Acids Res., 17, 3373 (1989).
43. F. Morvan, B. Rayner, and J.-L. Imbach, "α-Oligonucleotides: A unique class of modified chimeric nucleic acids," Anti-Cancer Drug Design, 6, 521 (1991).
44. C. Gagnor, B. Rayner, J.-P. Leonetti, et al., "α-DNA IX. Parallel annealing of α-anomeric oligodoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription," Nucleic Acids Res., 17, 5107 (1989).
45. J. L. Maher, III, B. Wold, and P. G. Dervan, "Inhibition of DNA binding properties by oligonucleotide-directed triple helix formation," Science, 245, 725 (1989).
46. P. S. Miller, "Non-ionic antisense oligonucleotides," in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, J. S. Cohen, Ed., CRC Press, Inc.,1989, p. 79,.
47. C. A. Stein and J. S. Cohen, "Phosphorothioate oligodeoxynucleotide analogues," in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, J. S. Cohen, Ed., CRC Press, Inc., p. 97, 1989.
48. C. Cazenave, C. A. Stein, N. Loreau, et al., "Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides," Nucleic Acids Res., 17, 4255 (1989).
49. R. Quartin, C. Brakel, and J. Wetmur, "Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates," Nucleic Acids Res., 17, 7253 (1989).
50. P. Furdon, Z. Dominski, and R. Kole, "RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," Nucleic Acid Res., 17, 9193 (1989).
51. P. S. Ederand J. A. Walder, "Ribonuclease H from K562 human erythroleukemia cells," J. Biol. Chem., 206, 6472 (1991).
52. B. P. Monia, E. A. Lesnik, C. Gonzalez, et al., "Evaluation of 2′ modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression," J. Biol. Chem., 268 (1993).
53. R. V. Giles and D. M. Tidd, "Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage of RNase H using chimeric methylphosphonodiester structures," Nucleic Acids Res., 20, 763 (1992).
54. R. Y. Walder and J. A. Walder, "Role of RNase H in hybrid-arrested translation by antisense oligonucleotides," Proc. Natl. Acad. Sci. U.S.A., 85, 5011 (1988).
55. J. Minshull and T. Hunt, "The use of single-stranded DNA and RNase H to promote quantitative hybrid arrest of translation of mRNA/DNA hybrids in reticulocyte lysate cell-free translations," Nucleic Acids Res., 14, 6433 (1986).
56. C. Gagnor, J. Bertrand, S. Thenet, et al., "Alpha-DNA VI: Comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition," Nucleic Acids Res., 15, 10419 (1987).
57. D. G. Knorre, V. V. Vlassov, and V. F. Zarytova, "Reactive oligonucleotide derivatives and sequence-specific modification of nucleic acids," Biochimie, 67, 785 (1985).
58. D. G. Knorre, V. V. Vlassov, and V. F. Zarytova, "Oligonucleotides linked to reactive groups," in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, J. S. Cohen, Ed., CRC Press, Inc.,1989, p. 173,.
59. V. V. Vlassov, V. F. Zarytova, I. V. Kutyavin, et al., "Sequence-specific chemical modification of a hybrid bacteriophage M13 single-stranded DNA by alkylating oligonucleotide derivatives," FEBS Lett., 231, 352 (1988).
60. J. Summerton and P. A. Bartlett, "Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5-dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA," J. Molec. Biol., 122, 145 (1978).
61. T. R. Webb and M. D. Matteucci, "Hybridization triggered crosslinking of leoxynucleotides," Nucleic Acids. Res., 14, 7661 (1986).
62. M. Cooney, G. Czernuszewic, E. H. Postel, et al., "Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro," Science, 241, 456 (1988).
63. H. E. Moser and P. B. Dervan, "Sequence specific cleavage of double helical DNA by triple helix formation," Science, 238, 650 (1987).
64. T. Le Doan, L. Perrouault, D. Praseuth, et al., "Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-[alpha]-thymidylate covalently linked to an azidoproflavine derivative," Nucleic Acids Res., 15, 7749 (1987).
65. O. S. Federova, D. G. Knoore, L. M. Podust, et al., "Complementary addressed modification of double-stranded DNA within a ternary complex," FEBS Lett., 228, 273 (1988).
66. D. Praseuth, L. Perrouault, T. Le Doan, et al., "Sequence-specific binding and photocrosslinking of [alpha] and [beta]-oligodeoxynucleotides to the major groove of DNA via triple helix formation," Proc. Natl. Acad. Sci. U.S.A., 85, 1349 (1988).
67. D. Praseuth, T. L. Doan, M. Chassignol, et al., "Sequence-targeted photosensitized reactions in nucleic acids by oligo-α-deoxynucleotides and oligo-β-deoxynucleotides covalently linked to proflavin," Biochemistry, 27, 3031 (1988).
68. T. Le Doan, L. Perrouault, M. Chassignol, et al., "Sequence-targeted chemical modifications of nucleic acids by complementary oligonucleotides covalently linked to porphyrins," Nucleic Acids Res., 15, 8643 (1987).
69. T. Le Doan, L. Perrouault, N. T. Thuong, et al., "Sequence-specific chemical and photochemical reactions on nucleic acids by oligonucleotides linked to porphyrins," J. Inorg. Biochem., 36, 274 (1989),(abstract.)
70. T. Le Doan, D. Praseuth, L. Perrouault, et al., "Sequence-targeted photochemical modifications of nucleic acids by complementary oligonucleotides covalently linked to porphyrins," Bioconj. Chem., 1, 108 (1990).
71. B. L. Lee, K. R. Blake, and P. S. Miller, "Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with synthetic DNA containing a promoter for T7 RNA polymerase," Nucleic Acids Res., 16, 10681 (1988).
72. B. L. Lee, A. Murakami, K. R. Blake, et al., "Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with single-stranded DNA," Biochem., 27, 3197 (1988).
73. D. Praseuth, M. Chassignol, M. Takasugi, et al., "Double helices with parallel strands are formed by nuclease-resistant oligo-[alpha]-deoxynucleotides and oligo-[alpha]-deoxynucleotides covalently linked to an intercalating agent with complementary oligo-[beta]-deoxynucleotides," J. Mol. Biol., 196, 939 (1987).
74. L. Perrouault, U. Asseline, C. Rivalle, et al., "Sequence-specific artificial photo-induced endonucleases based on triple-helix forming oligonucleotides," Nature, 344, 358 (1990).
75. C. Helene, "Artificial control of gene expression by oligonucleotides covalently linked to intercalating agents," Br. J. Cancer, 60, 157 (1989).
76. J. M. Kean, A. Murakami, K. R. Blake, et al., Photochemical cross-linking of psoralen-derivatized oligonucleotide methylphosphonates to rabbit globin messenger RNA," Biochemistry, 27, 9113 (1988).
77. T. Saison-Behmoaras, B. Tocque, I. Key, et al., "Short modified oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation," Embo J., 10, 1111 (1991).
78. P. B. Dervan, "Oligonucleotide recognition of double-helical DNA by triple-helix formation," in Oligodeoxynucleotide: Antisense Inhibitors of Gene Expression, J. S. Cohen, Ed., CRC Press, Inc.,1989, p. 197,.
79. H. E. Moser and P. B. Dervan, "Sequence-specific cleavage of double helical DNA by triple helix formation," Science, 238, 645 (1987).
80. B. C. F. Chu and L. E. Orgel, "Nonenzymatic sequence-specific cleavage of single-stranded DNA," Proc. Natl. Acad. Sci. U.S.A., 82, 963 (1985).
81. A. S. Boutorin, V. V. Vlassov, S. A. Kazakov, et al., "Complementary addressed reagents carrying EDTA-Fe(II) groups for directed cleavage of single-stranded nucleic acids," FEBS Lett., 172, 43 (1984).
82. 1,10-phenanthroline-copper complexes," Biochemistry, 27, 2272 (1988).
83. J. C. Francois, T. Saison-Behmoaras, C. Barbier, et al., "Sequence-specific recognition and cleavage of duplex DNA via triple helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate," Proc. Natl. Acad. Sci. U.S.A., 86, 9702 (1989).
84. 1,10-phenanthroline," J. Biol. Chem., 264, 5891 (1989).
85. C.-H.B. Chen and D. S. Sigman, "Nuclease activity of 1,10-phenanthroline-copper: Sequence-specific targeting," Proc. Natl. Acad. Sci. U.S.A., 83, 7147 (1986).
86. J. S. Sun, J. C. Francois, R. Lavery, et al., "Sequence-targeted cleavage of nucleic acids by oligo-[α]-thymidylate-phenanthroline conjugates: Parallel and anti-parallel double helices are formed with DNA and RNA, respectively," Biochem., 27, 6039 (1988).
87. C. Helene and N. T. Thuong, "Oligodeoxynucleotides covalently linked to intercalating agents and to nucleic acid-cleaving reagents. New families of gene regulatory substances," in Working Croup on Molecular Mechanisms of Carcinogenic and Antitumor Activity, C. Chagas and B. Pullman, Eds., Pontificaiae Academiae Scientarium Scripta Varia, Vatican City, 1987, p. 205,.
88. C. Helene and N. T. Thuong, "Control of gene expression by oligonucleotides covalently linked to intercalating agents," Genome, 31, 413 (1989).
89. T. R. Cech, "The chemistry of self-splicing RNA and RNA enzymes," Science, 236, 1532 (1987).
90. J. A. McSwiggen and T. R. Cech, "Stereochemistry of RNA cleavage by the tetrahymena ribozyme and evidence that the chemical step is not rate-limiting," Science, 244, 679 (1989).
91. O. C. Uhlenbeck, "Using ribozymes to cleave RNAs," in Antisense Research and Applications, S. T. Crooke and B. Lebleu, Eds., CRC Press, Boca Raton, FL, 1993, p. 83,.
92. J. Haseloff and W. L. Gerlach, "Simple RNA enzymes with new and highly specific endoribonuclease activities," Nature, 334, 585 (1988).
93. M. J. McCal, P. Hendry, and P. A. Jennings, "Minimal sequence requirements for ribozyme activity," Proc. Natl. Acad. Sci., 89, 5710 (1992).
94. B. M. Chowira, A. Berzal-Herranz, C. F. Keller, et al., "Four ribose 2′-hydroxyl groups essential for catalytic function of the hairpin ribozyme," J. Biol. Chem., 268, 19458 (1993).
95. 2+ binding," Biochem., 30, 5145 (1991).
96. O. Heidenreich, F. Benseler, A. Fahrenholz, et al., "High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates," J. Biol. Chem., 269, 2131 (1993).
97. W. A. Pieken, D. B. Olsen, F. Benseler, et al., "Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes," Science, 253, 314 (1991).
98. D. B. Olsen, F. Benseler, H. Aurup, et al., "Study of a hammerhead ribozyme containing 2′-modified adenosine residues," Biochem., 30, 9735 (1991).
99. J. Goodchild, "Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation," Nucleic Acids Res., 20, 4607 (1992).
100. A. C. Forester and S. Altman, "External guide sequences for an RNA enzyme," Science, 249, 783 (1990).
101. Y. Yuan, E.-S. Hwang, and S. Altman, "Targeted cleavage of mRNA by human RNase P," Proc. Natl. Acad. Sci., 89, 8006 (1992).
102. D. Herschlag and T. R. Cech, "DNA cleavage catalysed by the ribozyme from Tetrahymena," Nature, 344, 405 (1990).
103. E. De Clercq, F. Eckstein, and T. C. Merigan, "Interferon induction increased through chemical modification of a synthetic polyribonucleotide," Science, 165, 1137 (1969).
104. J. S. Cohen, "Phosphorothioate Oligodeoxynucleotides," in Antisense Research and Applications, S. T. Crooke and B. Lebleu, Eds., CRC Press, Boca Raton, FL,1993, p. 205,.
105. S. T. Crooke, "Therapeutic applications of oligonucleotides," Annu. Rev. Pharmacol. Toxicol., 32, 329 (1992).
106. S. T. Crooke, "Progress toward oligonucleotide therapeutics: Pharmacodynamic properties," FASEB J., 7, 533 (1993).
107. S. T. Crooke and B. Lebleu, Eds., Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993.
108. S. M. Freier, "Hybridization: Considerations affecting antisense drugs," in Antisense Research and Applications, S. T. Crooke and B. Lebleu, Eds., CRC Press, Boca Raton, FL,1993, p. 67, .
109. W. F. Lima, B. P. Monia, D. J. Ecker, et al., "Implication of RNA structure on antisense oligonucleotide hybridization kinetics," Biochem., 31, 12055 (1992).
110. R. W. Joos and W. H. Hall, "Determination of binding constants of serum albumin for penicillin," J. Pharmacol. Exp. Therap., 166, 113 (1969).
111. S. L. Loke, C. A. Stein, X. H. Zhang, et al., "Characterization of oligonucleotide transport into living cells," Proc. Natl. Acad. Sci. U.S.A., 86, 3474 (1989).
112. M. J. Graham, L. Cummins, M. E. Cooke, et al., "In vitro metabolism of phosphorothioate antisense oligonucleotides," Submitted, 1994.
113. W.- Y. Gao, F. -S. Han, C. Storm, et al., "Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology," Mol. Pharm., 41, 223 (1991).
114. S. Agrawal, J. Temsamani, and J. Y. Tang, "Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice," Proc. Natl. Acad. Sci. U.S.A., 88, 7595 (1991).
115. C. Majumdar, C. A. Stein, J. S. Cohen, et al., "Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligodeoxynucleotide," Biochem., 28, 1340 (1989).
116. Y.-C. Cheng, W. Gao, and F. Han, "Against human immunodeficiency virus and herpes viruses," Nucleosides & Nucleotides, 10, 155 (1991).
117. C. A. Stein, L. M. Neckers, B. C. Nair, et al., "Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 with gp120 to CD4," J. AIDS, 4, 686 (1991).
118. A. P. Fields, D. P. Bednarik, A. Hess, et al., "Human immunodeficiency virus induces phosphorylation of its cell surface receptor," Nature 333, 278 (1991).
119. G. D. Hoke, K. Draper, S. M. Freier, et al., "Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection," Nucleic Acids Res., 19, 5743 (1991).
120. E. Wickstrom, "Oligodeoxynucleotide stability in subcellular extracts and culture media," J. Biochem. Biophys. Methods, 13, 97 (1986).
121. J. M. Campbell, T. A. Bacon, and E. Wickstrom, "Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid," J. Biochem. Biophy. Meths., 20, 259 (1990).
122. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats," J. Pharmacol. and Exp. Therapy., 267, 1181 (1993).
123. R. M. Crooke, "In vitro toxicology and pharamacokinetics of antisense oligonucleotides," Anti-Cancer Drug Design, 6, 609 (1991).
124. R. M. Crooke," In vitro and in vivo toxicology of first generation analogs," in Antisense Research and Applications, S. T. Crooke and B. Lebleu, Eds., CRC Press, Boca Raton, FL, 1993, p. 471,.
125. R. M. Crooke, M. J. Graham, M. E. Cooke, et al., "In vitro pharmacokinetic analysis of phosphorothioate antisense oligonucleotides," J. Pharmacol. Exp. Ther., 275, 462 (1995).
126. L. M. Neckers, "Cellular internalization of oligodeoxynucleotides," in Antisense Research and Applications, S. T. Crooke and B. Lebleu, Eds., CRC Press, Inc., Boca Raton, FL, 1993, p. 451-460,.
127. L. A. Chrissey, S. E. Walz, M. Pazirandeh, et al., "Internalization of oligodeoxyribonucleotides by vibrio parahaemolyticus," Antisense Research and Develop., 3, 367 (1993).
128. C. F. Bennett, M.-Y. Chiang, H. Chan, et al., "Use of cationic lipids to enhance the biological activity of antisense oligonucleotides," J. Liposome Res., 3, 85 (1993).
129. C. F. Bennett, M.-Y. Chiang, H. Chan, et al., "Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides," Mol. Pharm., 41, 1023 (1992).
130. P. Iversen, "In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetic prologue," Anti-Cancer Drug Design, 6, 531 (1991).
131. 14C labeled phosphorothioate oligonucleotides, ISIS 2105, after intradermal administration to rats," J. Pharm. Exp. Therap., 269, 89 (1994).
132. 14C labeled afovirsen sodium in genital wart patients," Clin. Pharm. Therap., 56, 641-646 (1994).
133. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate," Mol. Pharm., 45, 932 (1994).
134. N. M. Dean and R. McKay, "Inhibition of PKC-α expression in mice after systemic administration of phosphorothioate antisense oligonucleotides," Proc. Nati Acad. Sci., 91, 11762-11766 (1994).
135. W. M. Galbraith, W. C. Hobson, P. C. Giclas, P. J. Schechter, and S. Agrawal, "Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey," Antisense Research & Develop., 4, 210-206 (1994).
136. M. Simons, E. R. Edelman, J.-L. DeKeyser, R. Langer, and R. D. Rosenberg, "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," Nature, 359, 67 (1992).
137. R. Morishita, G. H. Gibbons, K. E. Ellison, M. Nakajima, L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau, "Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia," Proc. Natl. Acad. Sci. U.S.A., 90, 8474 (1993).
138. J. Abe, W. Zhou, J. Taguchi, N. Takuwa, K. Miki, H. Okazaki, K. Kurokawa, M. Kumada, and Y. Takuwa, "Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and CDK2 oligonucleotides in rat carotid artery," Biochem. and Biophys. Res. Commun., 198, 16 (1994).
139. 1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery," Gene, 149, 13 (1994).
140. M. Simons, E. R. Edelman, and R. D. Rosenberg, "Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model," J. Clin. Invest., 93, 2351 (1994).
141. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin," Regulatory Peptides, 49, 167 (1993).
142. M. I. Phillips, D. Wielbo, and R. Gyurko, "Antisense inhibition of hypertension: A new strategy for renin-angiotensin candidate genes," Kidney Int., 46, 1554 (1994).
143. S. Suzuki, P. Pilowsky, J. Minson, L. Arnolda, I. J. Llewellyn-Smith, and J. Chalmers, "c-fos antisense in rostral ventral medulla reduces arterial blood pressure," Am. J. Physiol., 266, R1418 (1994).
144. R. M. Burch and L. C. Mahan, "Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice," J. Clin. Invest., 88, 1190 (1991).
145. S. M. Stepkowski, Y. Tu, T. P. Condon, and C. F. Bennett, "Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities," J. Immunology, 10, 5336 (1994).
146. L. Whitesell, A. Rosolen, and L. M. Neckers, "In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide," Antisense Res. & Dev., 1, 343 (1991).
147. I. Kitajima, T. Shinohara, J. Bilakovics, D. A. Brown, X. Xu, and M. Nerenberg, "Ablation of transplanted HTLF-1 tax-transformed tumors in mice by antisense inhibition of NF-kB," Science, 258, 1792 (1992).
148. M. Z. Ratajczak, J. A. Kant, S. M. Luger, N. Hijiya, J. Zhang, G. Zon, and A. M. Gewirtz, "In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides," Proc. Natl. Acad. Sci. U.S.A., 89, 11823 (1992).
149. L. Perlaky, Y. Saijo, R. K. Busch, C. F. Bennett, C. K. Mirabelli, B. T. Crooke, and H. Busch, "Growth inhibition of human tumor cell lines by antisense oligonlucleotides designed to inhibit p120 expression," Anti-Cancer Drug Design, 8, 3 (1993).
150. K. A. Higgins, J. R. Perez, T. A. Coleman, K. Dorshkind, W. A. McComas, U. M. Sarmiento, C. A. Rosen, and R. Narayanan, "Antisense inhibition of the p65 subunit of NF-kB blocks tumorigenicity and causes tumor regression," Proc. Natl. Acad. Sci. U.S.A., 90, 9901 (1993).
151. N. M. Dean and R. McKay, "Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides," Proc. Natl. Acad. Sci. U.S.A., 91, 11762 (1994).
152. N. Hijiya, J. Zhang, M. Z. Ratajczak, J. A. Kant, K. DeRiel, M. Herlyn, G. Zon, and A. M. Gewirtz, "Biological and therapeutic significant of MYB expression in human melanoma," Proc. Natl. Acad. Sci. U.S.A., 91, 4499 (1994).
153. G. Schwab, C. Chavany, I. Duroux, G. Goubin, J. Lebeau, C. Helene, and T. Saison-Behmoaras, "Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras mediated cell proliferation and tumorigenicity in nude mice," Proc. Natl. Acad. Sci. U.S.A., 91, 10460 (1994).
154. T. Skorski, M. Nieborowska-Skorska, N. C. Nicolaides, C. Szczylik, P. Iversen, R. V. Iozzo, G. Zon, and B. Calabretta, "Suppression of Philadelphia leukemia cell growth in mice by BCR0ABL antisense oligodeoxynucleotide," Proc. Natl. Acad. Sci. U.S.A., 91, 4504 (1994).
155. B. J. Chiasson, M. L. Hooper, P. R. Murphy, and H. A. Robertson, "Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain," Eur. J. Pharmacol., 227, 451 (1992).
156. A. Osen-Sand, M. Catsicas, J. K. Staple, K. A. Jones, G. Ayala, J. Knowles, G. Grenningloh, and S. Catsicas, "Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo," Nature, 364, 445 (1993).
157. A. Amaratunga, P. J. Morin, K. S. Kosik, and R. E. Fine, "Inhibition of kinesin synthesis and rapid anterograde anxonal transport in vivo by an antisense oligonucleotide," J. Biol. Chem., 268, 17427 (1993).
158. L. M. Flanagan, M. M. McCarthy, P. J. Brooks, D. W. Pfaff, and B. S. McEwen, "Arginine vasopressin levels after daily infusions of antisense oligonucleotides into the supraoptic nucleus," Ann. NY Acad. Sci., 689, 520 (1993).
159. M. Heilig, J. A. Engel, and B. Soderpalm, "C-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine," Eur. J. Pharmacol., 236, 339 (1993).
160. G. Pollio, P. Xue, M. Zanisi, A. Nicolin, and A. Maggi, "Antisense of oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats," Mol. Brain Res., 19, 135 (1993).
161. 2 receptors: Behavioral correlates," Neurosci. Lett., 161, 4947 (1993).
162. C. Wahlestedt, E. Galonov, S. Yamamoto, F. Yee, H. Ericson, H. Yoo, C. E. Inturrisi, and D. J. Reis, "Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions," Nature, 363, 260 (1993).
163. A. Akabayashi, C. Wahlestedt, J. T. Alexander, and S. F. Leibowitz, "Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion," Mol. Brain Res., 21, 55 (1994).
164. J. U. Adams, X. H. Chen, J. K. DeRiel, M. W. Adler, and L.-Y. Liu-Chen, "In vivo treatment with antisense oligodeoxynucleotide to kappa-opioid receptors inhibited kappa-agonist-induced analgesia in rats," Regul. Pept., 54, 1 (1994).
165. M. A. Castro-Alamancos and I. Torres-Aleman, "Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide," Proc. Natl. Acad. Sci. U.S.A., 91, 10203 (1994).
166. J. U. Adams, X. H. Chen, J. K. DeRiel, M. W. Adler, and L.-Y. Liu-Chen, "Intracerebrovenetricular treatment with an antisense oligodeoxynucleotide to kappa-opiod receptors inhibited kappa-agonist-induced analgesia in rats," Brain Res., 667, 129 (1994).
167. F. Gillardon, H. Beck, E. Uhlmann, T. Herdegen, J. Sandkuhler, A. Peyman, and M. Zimmerman, "Inhibition of c-fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion," Eur. J. Neurosci., 6, 880 (1994).
168. M. L. Hooper, B. J. Chiasson, and H. A. Robertson, "Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioral effect," Neuroscience, 63, 917 (1994).
169. V. L. Woodburn, J. C. Hunter, C. Durieux, J. A. Post, and J. Hughes, "The effect of c-fos antisense in the formalin-paw test," Regul. Pept., 54, 327 (1994).
170. M. S. Kindy, "NMDA receptor inhibition using antisense oligonucleotides prevents delayed neuronal death in gerbil hippocampus following cerebral ischemia," Neurosci. Res. Commun., 14, 175 (1994).
171. C. Konradi, R. L. Cole, S. Heckers, and S. E. Hyman, "Amphetamine regulates gene expression in rat striatum via transcription factor CREB," J. Neurosci., 14, 5623 (1994).
172. 2-agonist antinociception," Neuroreport, 5, 1049 (1994).
173. S. K. Mani, J. D. Blaustein, J. M. C. Allen, S. W. Law, B. W. O'Malley, and H. J. Clark, "Inhibition of rat sexual behavior by antisense oligonucleotides to the progesterone receptor," Endocrinology, 135 (1994).
174. M. M. McCarthy, D. B. Masters, K. Rimvall, S. Schwartz-Gilbin, and D. W. Pfaff, "Intracerebral administration of antisense oligodeoxynucleotides to GAD65 and GAD67 mRNAs modulate reproductive behavior in the female rat," Brain Res., 636, 209 (1994).
175. I. Neuman, D. W. F. Porter, R. Landgraft, and Q. J. Pittman, "Rapid effect on suckling of an oxytocin antisense oligonucleotide administered into rat supraoptic nucleus," Am. J. Physiol., 267, R852 (1994).
176. H. Ogo, Y. Hirai, S. Miki, H. Nishio, M. Akiyama, and Y. Nakata, "Modulation of substance P/neurokinin-1 receptor in human astrocytoma cells by antisense oligodeoxynucleotides," Gen. Pharmacol., 25, 1131 (1994).
177. T. Skutella, J. C. Probst, G. F. Jirikowski, F. Holsboer, and R. Spanagel, "Ventral tegmental area (VTA) injections of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppress operant behavior in rats," Neurosci. Lett., 167, 55 (1994).
178. W. Tischmeyer, R. Grimm, H. Schicknick, W. Brysch, and K.-H. Schlingensiepen, "Sequence-specific impairment of learning by c-jun antisense oligonucleotides," Neuroreport, 5, 1501 (1994).
179. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine," J. Pharmacol. Exp. Ther., 271, 1462 (1994).
180. 2 dopamine receptors in mouse striatum," J. Pharmacol. Exp. Ther., 268, 1015 (1994).
181. M. Kula, C. C. Smith, L. Aurelian, R. Rishelevich, K. Meade, P. Miller, and P. O. P. Ts'o, "Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4," Proc. Natl. Acad. Sci. U.S.A., 86, 6868 (1989).
182. V. V. Vlassov, "Inhibition of tick-borne viral encephalitis expression using covalently linked oligonucleotide analogs," meeting on Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression: Therapeutic Implications, Rockville, MD, June 18-21, 1989.
183. W.-B. Offensperger, S. Offensperger, E. Walter, K. Teubner, G. Igloi, H. E. Blum, and W. Gerok, "In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," The EMBO Journal 12, 1257 (1993).